These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32815556)

  • 21. Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
    Zuo Y; Yang D; Yu Y; Xiang M; Li H; Yang J; Li J; Jiang D; Zhou H; Xu Z; Yu Z
    Mol Med Rep; 2018 Mar; 17(3):3497-3502. PubMed ID: 29257330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL.
    Zhan M; Qu Q; Wang G; Zhou H
    Pharmazie; 2013 Dec; 68(12):955-61. PubMed ID: 24400442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.
    Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J
    J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
    Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
    PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
    Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
    Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
    Tian W; Sun Y; Cheng Y; Ma X; Du W; Shi W; Guo Q
    Thorac Cancer; 2021 Oct; 12(19):2551-2563. PubMed ID: 34469060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of Ras-related protein 25 predicts chemotherapy resistance and prognosis in advanced non-small cell lung cancer.
    Ma YF; Yang B; Li J; Zhang T; Guo JT; Chen L; Li M; Chu J; Liang CY; Liu Y
    Genet Mol Res; 2015 Oct; 14(4):13998-4008. PubMed ID: 26535714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-125b-5p upregulation by TRIM28 induces cisplatin resistance in non-small cell lung cancer through CREB1 inhibition.
    Tan Q; Ma J; Zhang H; Wu X; Li Q; Zuo X; Jiang Y; Liu H; Yan L
    BMC Pulm Med; 2022 Dec; 22(1):469. PubMed ID: 36476351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ginsenoside Rb
    Niu X; Shi Y; Li Q; Chen H; Fan X; Yu Y; Lv C; Lu J
    Phytomedicine; 2023 Jul; 115():154776. PubMed ID: 37087793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
    Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
    Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p32/OPA1 axis-mediated mitochondrial dynamics contributes to cisplatin resistance in non-small cell lung cancer.
    Yu CX; Peng ZQ; Wang T; Qu XH; Yang P; Huang SR; Jiang LP; Tou FF; Han XJ
    Acta Biochim Biophys Sin (Shanghai); 2024 Jan; 56(1):34-43. PubMed ID: 38151998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
    Ju ZS; Sun B; Bao D; Zhang XF
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
    Ma Y; Li X; Cheng S; Wei W; Li Y
    Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
    Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
    Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
    Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
    J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
    Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
    Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
    Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.